AdvIL-2

重组人白介素2腺病毒

Report date: 2023/10/26 16:47:10

Base Information

Drug NameAdvIL-2
Drug Alias Name重组人白介素2腺病毒抗癌注射液AdvIL2
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionInterleukin-2 receptor agonistsGene transference
TargetsInterleukin-2 receptor
Therapy Area/IndicationsHematologic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (IND)
Highest Status in ChinaPending
Originator CompaniesChengdu Huasun Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesChengdu Huasun Technology Group Inc Ltd
Active IndicationsN/A
Inactive IndicationsHematologic Diseases

Other Information

ATC CodeN/A
Related LinksN/A